New Alzheimer's drug clears FDA advisory vote despite unknowns

Jennifer Couzin-Frankel

DOI: https://doi.org/10.1126/science.adr0291

IF: 56.9

2024-06-15

Science

Abstract:Pivotal trial of Eli Lilly's donanemab leaves questions about how to prescribe it and minimize risks

multidisciplinary sciences

What problem does this paper attempt to address?

Alzheimer's drug with modest benefits wins backing of FDA advisers

Sara Reardon

DOI: https://doi.org/10.1038/d41586-024-01726-w

IF: 64.8

2024-06-11

Nature

Abstract:Donanemab slows progression of symptoms, but questions linger about the durability of its effect. Donanemab slows progression of symptoms, but questions linger about the durability of its effect.

multidisciplinary sciences
Alzheimer's drug approvals create prescribing dilemmas

Jennifer Couzin-Frankel

DOI: https://doi.org/10.1126/science.adu2383

IF: 56.9

2024-11-01

Science

Abstract:Clinicians and patients weigh modest benefits of the antibodies against sometimes-serious side effects

multidisciplinary sciences
Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's

Tanya Song,Yunfei Wang,Bret David Silverglate,George T. Grossberg

DOI: https://doi.org/10.1080/17425255.2024.2357637

2024-05-22

Expert Opinion on Drug Metabolism & Toxicology

Abstract:Introduction Donanemab is a humanized monoclonal antibody that significantly reduces cerebral amyloid plaques in Alzheimer's Disease (AD). It can delay disease progression and cognitive decline, making it one of the most promising disease-modifying treatments in the current treatment landscape.

pharmacology & pharmacy,biochemistry & molecular biology,toxicology
Landmark Alzheimer’s drug approval confounds research community

Asher Mullard

DOI: https://doi.org/10.1038/d41586-021-01546-2

IF: 64.8

2021-06-08

Nature

Abstract:Many scientists say there is not enough evidence that Biogen's aducanumab is an effective therapy for the disease. Many scientists say there is not enough evidence that Biogen's aducanumab is an effective therapy for the disease.

multidisciplinary sciences
FDA Considers Alzheimer’s Drug Previously Abandoned for Lack of Effectiveness

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.l6164

2019-01-01

Abstract:An Alzheimer’s drug that failed in two phase III trials and was abandoned as valueless has been brought back to life after an intensive examination of the trial results showed that it just might work in patients with early stage disease if the dose is right. Aducanumab, developed by Biogen, joined a long list of failed Alzheimer’s treatments in March this year after the two trials found that it failed to slow the course of the disease. A similar drug from Eli Lilly also failed,1 leading analysts to conclude that the search for a treatment that was based on attacking amyloid plaques, the pathological signature of the disease, was doomed. The failure hit Biogen hard, as it had created big expectations for aducanumab. So, drug company analysts showed …
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Ivelina Gueorguieva,Brian A. Willis,Laiyi Chua,Kay Chow,C. Steven Ernest,Sergey Shcherbinin,Paul Ardayfio,Garrett R. Mullins,John R. Sims

DOI: https://doi.org/10.1002/cpt.2875

2023-03-09

Clinical Pharmacology & Therapeutics

Abstract:Donanemab is an amyloid-targeting therapy that resulted in robust amyloid plaque reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the phase II TRAILBLAZER-ALZ study (NCT03367403). The objectives of the current analyses are to characterize (i) the population pharmacokinetics of donanemab, (ii) the relationship between donanemab exposure and amyloid plaque reduction (response), and (iii) the relationship between donanemab exposure and amyloid-related imaging abnormalities with edema or effusions (ARIA-E). Model development included data from participants with mild cognitive impairment or mild to moderate dementia due to AD from the phase Ib study on donanemab (NCT02624778) and participants with early symptomatic AD from the TRAILBLAZER-ALZ study. The analysis showed donanemab has a terminal elimination half-life of 11.8 days. Body weight and antidrug antibody titer impact donanemab exposure but not the pharmacodynamic response. Maintaining a donanemab serum concentration above 4.43 μg/mL (95% confidence interval: 0.956, 10.4) is associated with amyloid plaque reduction. The time to achieve amyloid plaque clearance (amyloid plaque level < 24.1 Centiloids) varied depending on the baseline amyloid level, where higher baseline levels were associated with fewer participants achieving amyloid clearance. The majority of participants achieved amyloid clearance by 52 weeks on treatment. Apolipoprotein ε4 carriers, irrespective of donanemab serum exposure, were 4 times more likely than noncarriers to have an ARIA-E event by 24 weeks.

pharmacology & pharmacy
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?

Jordan Beveridge,Eileen Kaniecki,Aniketh Naidu,Bret David Silverglate,George Grossberg

DOI: https://doi.org/10.1080/14728214.2024.2304059

2024-01-14

Expert Opinion on Emerging Drugs

Abstract:Introduction Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval. There are three different drugs approved or pending FDA-approval: aducanumab, lecanemab, and donanemab. These three drugs are each in different stages of regulatory approval by the FDA.

pharmacology & pharmacy
Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?

Giovanna Lalli,Jonathan M Schott,John Hardy,Bart De Strooper

DOI: https://doi.org/10.15252/emmm.202114781

2021-08-02

EMBO Molecular Medicine

Abstract:On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer's disease in almost 20 years—and notably, the first drug with a putative disease-modifying mechanism for the treatment of this devastating disorder, namely the removal of β-amyloid (or Aβ) plaques from the brain.

medicine, research & experimental
How donanemab data address the coverage with evidence development questions

Eric G. Klein,Krista Schroeder,Alette Wessels,Adam Phipps,Maureen Japha,Traci Schilling,Jennifer A. Zimmer

DOI: https://doi.org/10.1002/alz.13700

2024-02-09

Alzheimer s & Dementia

Abstract:The Centers for Medicare & Medicaid Services (CMS) established a class‐based National Coverage Determination (NCD) for monoclonal antibodies directed against amyloid for Alzheimer's disease (AD) with patient access through Coverage with Evidence Development (CED) based on three questions. This review, focused on donanemab, answers each of these CED questions with quality evidence. TRAILBLAZER‐ALZ registration trials are presented with supporting literature and real‐world data to answer CED questions for donanemab. TRAILBLAZER‐ALZ registration trials demonstrated that donanemab significantly slowed cognitive and functional decline in amyloid‐positive early symptomatic AD participants, and lowered their risk of disease progression while key safety risks occurred primarily within the first 6 months and then declined. Donanemab meaningfully improved health outcomes with a manageable safety profile in an early symptomatic AD population, representative of Medicare populations across diverse practice settings. The donanemab data provide the necessary level of evidence for CMS to open a reconsideration of their NCD. Highlights Donanemab meaningfully improved outcomes in trial participants with early symptomatic Alzheimer's disease. Comorbidities in trial participants were consistent with the Medicare population. Co‐medications in trial participants were consistent with the Medicare population. Risks associated with treatment tended to occur in the first 6 months. Risks of amyloid‐related imaging abnormalities were managed with careful observation and magnetic resonance imaging monitoring.

clinical neurology
1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial

M Mintun,C Ritchie,P Solomon,J R Sims,S Salloway,O Hansson,L G Apostolova,J A Zimmer,C D Evans,M Lu,P Ardayfio,J D Sparks,A M Wessels,S Shcherbinin,H Wang,E S M Nery,E C Collins,E B Dennehy,D A Brooks,D M Skovronsky,A Farquharson (Non-author presenter),

DOI: https://doi.org/10.1093/ageing/afad246.112

2024-01-01

Age and Ageing

Abstract:Abstract Introduction In TRAILBLAZER-ALZ donanemab (DONA) cleared brain amyloid plaques, significantly slowing disease progression in early symptomatic Alzheimer’s disease (ESAD). Methods: TRAILBLAZER-ALZ2 enrolled participants with ESAD and amyloid and tau pathology by positron-emission tomography, randomizing (multicenter) those with low/medium-tau (n=1182) and high-tau (n=552) (missing tau n=2). Participants (randomized double-blind,1:1) received DONA (n=860)/placebo (n=876) IV every 4w for 72w. DONA participants meeting amyloid clearance treatment completion criteria at 24/52w had blinded switched to placebo. Primary outcomes Integrated AD Rating Scale(iADRS) change from baseline at 76w in low/medium-tau or combined (low/medium- and high-tau) populations. Statistical testing allocated most power (80% α spend) to low/medium-tau population outcomes, with the remainder for combined population outcomes, including clinical and biomarker assessments. Results In the low/medium-tau population iADRS change at 76w: −6.02 (DONA) and −9.27 (placebo) (difference 3.25; 95%CI, 1.88-4.62; P<0.001), 35.1% slowing of disease progression. Change in Clinical Dementia Rating Scale (CDR)–Sum of Boxes: 1.20 (DONA) and 1.88 (placebo) (difference −0.67; 95% CI −0.95 to −0.40; P<0.001), 36.0% slowing. Participants receiving DONA experienced 38.6% less risk of progressing to next disease stage vs placebo over 76w (CDR-Global score, HR=0.61; P<0.001). Amyloid clearance at 24/52/76w: achieved in 34.2%/71.3%/80.1% DONA-treated participants. Significant, positive results were observed in the combined population. Serious AEs: 17.4% (DONA), and 15.8% (placebo), with 3 deaths among DONA patients who experienced serious amyloid-related imaging abnormalities (ARIA). AEs with DONA included ARIA-E (24.0%, 6.1% symptomatic); ARIA-H (31.4%); infusion-related reactions (8.7%). Conclusion DONA treatment significantly slowed clinical progression at 76w with a safety profile consistent with earlier studies. Presented: AAIC2023.

geriatrics & gerontology,gerontology
Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies

Leonardino A. Digma MD,Joseph R. Winer PhD,Michael D. Greicius MD

2023-11-19

Abstract:Alzheimer's disease (AD) is a prevalent, progressive, and ultimately fatal neurodegenerative disorder that is defined pathologically by the accumulation of amyloid plaques and tau neurofibrillary tangles in the brain. There remains an unmet need for therapies that can halt or slow the course of AD. To address this need, the FDA has provided a mechanism, under its Accelerated Approval pathway, for potential therapeutics to be approved based in part on their ability to reduce brain amyloid. Through this pathway, two monoclonal anti-amyloid antibodies, aducanumab and lecanemab, have been approved for clinical use. More recently, another amyloid-lowering antibody, donanemab, generated a statistically significant outcome in a phase 3 clinical trial and will shortly come under FDA review. While these monoclonal antibodies are not yet routinely used in clinical practice, the series of recent positive clinical trials has fostered enthusiasm amongst some AD experts. Here, we discuss three key limitations regarding recent anti-amyloid clinical trials: (1) there is little to no evidence that amyloid reduction correlates with clinical outcome, (2) the reported efficacy of anti-amyloid therapies may be partly, or wholly, explained by functional unblinding, and (3) donanemab in its phase 3 trial had no effect on tau burden, the pathological hallmark more closely related to cognition. Taken together, these observations call into question the efficacy of anti-amyloid therapies.

Tissues and Organs
Can we learn lessons from the FDA's approval of aducanumab?

Kathy Y Liu,Robert Howard

DOI: https://doi.org/10.1038/s41582-021-00557-x

Abstract:On 7 June 2021, aducanumab was granted accelerated approval for the treatment of Alzheimer disease (AD) by the FDA on the basis of amyloid-lowering effects considered reasonably likely to confer clinical benefit. This decision makes aducanumab the first new drug to be approved for the treatment of AD since 2003 and the first drug to ever be approved for modification of the course of AD. Many have questioned how scientific evidence, expert advice and the best interests of patients and families were considered in the approval decision. In this article, we argue that prior to approval, the FDA and Biogen's shared interpretation of clinical trial data - that high-dose aducanumab was substantially clinically effective - avoided conventional scientific scrutiny, was prominently advanced by patient representative groups who had been major recipients of Biogen funds, and raised concerns that safeguards were insufficient to mitigate regulatory capture within the FDA. Here, we reflect on events leading to the FDA's decision on 7 June 2021 and consider whether any lessons can be learned for the field.
Lecanemab's Path Forward: Navigating the Future of Alzheimer's Treatment in Europe Amidst the EMA's Rejection

Alessandro Martorana,Chiara Giuseppina Bonomi,Martina Gaia Di Donna,Caterina Motta

DOI: https://doi.org/10.1007/s40120-024-00675-w

2024-11-04

Neurology and Therapy

Abstract:Lecanemab (Leqembi © , Biogen), a humanized anti-amyloid-beta monoclonal antibody, has been approved for early-stage Alzheimer's disease (AD) in several countries, including the US and Japan. However, the European Medicines Agency (EMA) recently issued a negative opinion on its marketing authorization, reflecting concerns over the clinical value and manageability of anti-amyloid treatments. This decision highlights the ongoing disconnect between research advancements and clinical practice, where the focus on biological markers over tangible clinical improvements remains contentious. Despite promising biological effects, lecanemab's clinical outcomes have been modest, raising questions about its therapeutic role. The EMA's refusal underscores the need to address doubts surrounding the real-world effectiveness and safety of such treatments, especially concerning amyloid-related imaging abnormalities (ARIAs), a common side effect observed in clinical trials. The recent approval of lecanemab by the UK's Medicines and Healthcare products Regulatory Agency, despite the National Institute for Health and Care Excellence's rejection on cost-effectiveness grounds, further fuels the debate on the feasibility of anti-amyloid therapies. This commentary emphasizes the importance of real-world data on lecanemab's impact on cognitive decline, daily functioning, and side-effect management. As the global clinical use of lecanemab increases, continuous and standardized reporting on its outcomes is crucial for guiding future regulatory decisions and for potentially bridging the gap between research and practice in AD treatment.

clinical neurology
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials

Wenxue Wu,Yi Ji,Zilan Wang,Xiaoxiao Wu,Jiaxuan Li,Feng Gu,Zhouqing Chen,Zhong Wang

DOI: https://doi.org/10.1186/s40001-023-01512-w

IF: 4.981

2023-11-29

European Journal of Medical Research

Abstract:Alzheimer's disease (AD) is a worldwide public health problem and is difficult to cure. Drugs aimed at slowing the progression of the disease have been developed, with the Food and Drug Administration (FDA) granting accelerated approval for aducanumab on June 21, 2021 and a new accelerated approval for lecanemab on January 22, 2023. We performed this systematic review and meta-analysis to assess the efficacy and safety of FDA-approved anti-amyloid-β (anti-Aβ) monoclonal antibodies (mabs) for the treatment of AD.

medicine, research & experimental
Lecanemab Questions

Stephen E Nadeau,Stephen E. Nadeau

DOI: https://doi.org/10.1212/wnl.0000000000209320

IF: 9.9

2024-04-09

Neurology

Abstract:The recently published results of the 18-month randomized controlled trial of lecanemab, reporting the efficacy of the drug in slowing the progression of early Alzheimer disease, quickly led to approval by the FDA and widespread acceptance of lecanemab treatment. However, there are a number of matters that deserve further consideration. The success of blinding was not assessed, even as infusion reactions and the cerebral pathology underlying amyloid-related imaging abnormalities could have signaled to many participants that they were on drug, potentially exerting a potent placebo effect. The value of the outcome to participants is not defined in the absolute terms necessary for clinical decision-making, and the difference attributable to lecanemab was between 18% and 46% of estimates of the minimal clinically important difference on the Clinical Dementia Rating Scale Sum of Boxes. The attenuation of change on the Alzheimer's Disease Assessment Scale-Cognitive 14 achieved by lecanemab at 18 months was 50% of that achieved by donepezil at 6 months. Lecanemab treatment imposes a high treatment burden. The fact that the burden commences at the initiation of lecanemab treatment, whereas the benefit accrues years later requires us to take into account value discounting over time, which would significantly reduce the benefit/burden ratio. Finally, treatment with monoclonal antibodies to cerebral amyloid has consistently been associated with progressive cerebral atrophy. At the least, these issues should be raised in treatment discussions with patients. They also suggest a need to very seriously reconsider how we evaluate clinical trial results preparatory to translating them into clinical practice. Some suggestions are provided.

clinical neurology
The Problem of Aducanumab for the Treatment of Alzheimer Disease

G Caleb Alexander,Jason Karlawish,G. Caleb Alexander

DOI: https://doi.org/10.7326/M21-2603

IF: 39.2

2021-06-18

Annals of Internal Medicine

Abstract:On 7 June 2021, the U.S. Food and Drug Administration (FDA) approved aducanumab for the treatment of Alzheimer disease. Biogen, the owner of the drug, will sell it as Aduhelm. The FDA's decision to approve aducanumab is among its most controversial ever. In this article, we examine the decision's implications for clinical research and patient care.

medicine, general & internal
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-{beta}-amyloid Monoclonal Antibodies in Early Alzheimer's Disease

Michelle Jin,James M. Noble

DOI: https://doi.org/10.1523/eneuro.0088-24.2024

2024-09-28

eNeuro

Abstract:A new era of disease-modifying therapy for Alzheimer's disease (AD) arrived in 2021 following the Food and Drug Administration's (FDA) decision to grant accelerated approval for aducanumab, an anti-β-amyloid (Aβ) monoclonal antibody designed to target Aβ aggregates, a biological component of AD. More recently, trial outcomes for lecanemab and donanemab, two additional antibodies of this drug class, have shown favorable and significant slowing of metrics for cognitive and functional decline. Lecanemab and donanemab have since received similar FDA approval to aducanumab in January 2023 and July 2024, respectively. Given that these therapies are a clearly emerging tool in the repertoire of clinicians treating AD and related dementias, a critical dialogue has been ongoing regarding the potential impacts and place for these therapies. Here, we seek to contextualize this debate by first considering factors involved in theoretically extrapolating current randomized control trial outcomes to estimate meaningful clinical impacts. In the process of this exercise, we outline a generally useful concept termed Summative Treatment-Associated Benefit measuring Long-term Efficacy/Effectiveness Area as a metric of summative benefits of treatment over the life course of an individual. Second, we consider current real-world factors, such as conditions of FDA approval and other points involved in clinical decision-making that will influence and/or temper the actual impacts of this drug class.

neurosciences
High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects

N Villain,V Planche,R Levy

DOI: https://doi.org/10.1016/j.neurol.2022.06.012

Abstract:In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results on a putative biological surrogate marker. This approval has raised an unprecedented controversy. It was followed by a refusal of the European Medicine Agency, which does not allow the marketing of drugs solely on biological arguments and raised safety issues, and important US coverage limitations by the Centers for Medicare & Medicaid Services. Two other anti-amyloid immunotherapies showed significant results regarding a clinical outcome in phase 2 trials, and five drugs are being studied in phase 3 trials. Compared to those tested in previous trials of the 2010s, the common feature and novelty of these anti-amyloid immunotherapies is their ability to induce a high clearance of amyloid load, as measured with positron emission tomography, in the brain of early-stage biomarker-proven AD patients. Here, we review the available evidence regarding efficacy and safety data and medico-economical aspects for high-clearance anti-amyloid immunotherapies. We also perform frequentist and Bayesian meta-analyses of the clinical efficacy and safety of the highest dose groups from the two aducanumab phase 3 trials and the donanemab and lecanemab phase 2 trials. When pooled together, the data from high-clearance anti-amyloid immunotherapies trials confirm a statistically significant clinical effect of these drugs on cognitive decline after 18 months (difference in cognitive decline measured with CDR-SB after 18 months between the high dose immunotherapy groups vs. placebo = -0.24 points; P=0.04, frequentist random-effect model), with results on ADAS-Cog being the most statistically robust. However, this effect remains below the previously established minimal clinically relevant values. In parallel, the drugs significantly increased the occurrence of amyloid-related imaging abnormalities-edema (ARIA-E: risk ratio=13.39; P<0.0001), ARIA-hemorrhage (risk ratio=2.78; P=0.0002), and symptomatic and serious ARIA (7/1321=0.53% in the high dose groups versus 0/1446 in the placebo groups; risk ratio=6.44; P=0.04). The risk/benefit ratio of high-clearance immunotherapies in early AD is so far questionable after 18 months. Identifying subgroups of better responders, the perspective of combination therapies, and a longer follow-up may help improve their clinical relevance. Finally, the preliminary evidence from medico-economical analyses seems to indicate that the current cost of aducanumab in the US is not in reasonable alignment with its clinical benefits.
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease

Michelle Jin,James M Noble

DOI: https://doi.org/10.1523/ENEURO.0088-24.2024

2024-09-27

eNeuro

Abstract:A new era of disease-modifying therapy for Alzheimer's disease (AD) arrived in 2021 following the Food and Drug Administration's (FDA) decision to grant accelerated approval for aducanumab, an anti-β-amyloid (Aβ) monoclonal antibody designed to target Aβ aggregates, a biological component of AD. More recently, trial outcomes for lecanemab and donanemab, two additional antibodies of this drug class, have shown favorable and significant slowing of metrics for cognitive and functional decline. Lecanemab and donanemab have since received similar FDA approval to aducanumab in January 2023 and July 2024, respectively. Given that these therapies are a clearly emerging tool in the repertoire of clinicians treating AD and related dementias, a critical dialogue has been ongoing regarding the potential impacts and place for these therapies. Here, we seek to contextualize this debate by first considering factors involved in theoretically extrapolating current randomized control trial outcomes to estimate meaningful clinical impacts. In the process of this exercise, we outline a generally useful concept termed Summative Treatment-Associated Benefit measuring Long-term Efficacy/Effectiveness Area as a metric of summative benefits of treatment over the life course of an individual. Second, we consider current real-world factors, such as conditions of FDA approval and other points involved in clinical decision-making that will influence and/or temper the actual impacts of this drug class.

New Alzheimer's drug clears FDA advisory vote despite unknowns

Alzheimer's drug with modest benefits wins backing of FDA advisers

Alzheimer's drug approvals create prescribing dilemmas

Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's

Landmark Alzheimer’s drug approval confounds research community

FDA Considers Alzheimer’s Drug Previously Abandoned for Lack of Effectiveness

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?

How donanemab data address the coverage with evidence development questions

1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial

Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies

Can we learn lessons from the FDA's approval of aducanumab?

Lecanemab's Path Forward: Navigating the Future of Alzheimer's Treatment in Europe Amidst the EMA's Rejection

The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials

Lecanemab Questions

The Problem of Aducanumab for the Treatment of Alzheimer Disease

What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-{beta}-amyloid Monoclonal Antibodies in Early Alzheimer's Disease

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects

What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease